Search Result
Results for "
Acyltransferase Inhibitor
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-10038
-
A 922500
Maximum Cited Publications
30 Publications Verification
DGAT-1 Inhibitor 4a
|
Acyltransferase
|
Metabolic Disease
|
|
A 922500 (DGAT-1 Inhibitor 4a) is a potent, selective, and orally bioavailable diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC50s of 9 and 22 nM against human and mouse DGAT-1, respectively.
|
-
-
- HY-108341A
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
|
-
-
- HY-N6719
-
Fumonisin B1
Maximum Cited Publications
9 Publications Verification
|
Acyltransferase
|
Infection
|
|
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .
|
-
-
- HY-108341
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
|
-
-
- HY-100400A
-
-
-
- HY-113054
-
|
|
Acyltransferase
Bacterial
Endogenous Metabolite
|
Infection
Metabolic Disease
|
|
DL-Glyceraldehyde 3-phosphate is an intermediate in several metabolic pathways, including glycolysis and gluconeogenesis. DL-Glyceraldehyde 3-phosphate is a potent inhibitor of the growth of E. coli. DL-Glyceraldehyde 3-phosphate is a competitive inhibitor of the acyltransferase .
|
-
-
- HY-13009
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
PF-04620110 is a potent, selective and orally bioavailable diglyceride acyltransferase-1 (DGAT-1) inhibitor with an IC50 of 19 nM .
|
-
-
- HY-112489
-
-
-
- HY-N4193
-
Glabrol
3 Publications Verification
|
Acyltransferase
|
Cardiovascular Disease
|
|
Glabrol (Compound 1), One isoprenyl flavonoid was isolated from ethanol extract of licorice roots, is a potent and non-competitive Acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor with an IC50 value of 24.6 μM for rat liver microsomal ACAT activity .
|
-
-
- HY-15497
-
AZD7687
1 Publications Verification
|
Acyltransferase
|
Metabolic Disease
|
|
AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research .
|
-
-
- HY-117832
-
-
-
- HY-107572
-
|
CI 976
|
Acyltransferase
|
Metabolic Disease
|
|
PD 128042 (CI 976) is a potent, orally active, and selective inhibitor of ACAT (acyl coenzyme A:cholesterol acyltransferase) with an IC50s of 73 nM. PD 128042 is also a potent LPAT (lysophospholipid acyltransferase) inhibitor. PD 128042 inhibits Golgi-associated LPAT activity (IC50=15 μM). PD 128042 inhibits multiple membrane trafficking steps, including ones found in the endocytic and secretory pathway .
|
-
-
- HY-100399
-
|
PD-132301; ATR-101
|
Acyltransferase
Apoptosis
|
Cancer
|
|
Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer .
|
-
-
- HY-100399A
-
|
PD-132301 hydrochloride; ATR101 hydrochloride
|
Acyltransferase
Apoptosis
|
Cancer
|
|
Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .
|
-
-
- HY-12425
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
DGAT1-IN-1 is a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor with a human IC50 of <10 nM and a mouse IC50 of <50 nM. DGAT1-IN-1 is applicable to the research of obesity-related diseases, type 2 diabetes and diabetes-related diseases .
|
-
-
- HY-105445
-
-
-
- HY-153628
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
GPAT-IN-1 is a glycerol-3-phosphate acyltransferase (GPAT) inhibitor with an IC50 value of 8.9 μM. GPAT-IN-1 can be used for the research of obesity .
|
-
-
- HY-101857
-
|
MGAT2-IN-1
|
Acyltransferase
|
Metabolic Disease
|
|
TP-020 (MGAT2-IN-1), a chemical probe, is an orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC50 of 7.8 and 2.4 nM for human and mouse MGAT2, respectively.
|
-
-
- HY-16437
-
-
-
- HY-121254
-
-
-
- HY-N10788
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
Pomonic acid is an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor. Pomonic acid reduces the esterification of free cholesterol to cholesteryl esters and the accumulation of intracellular cholesteryl esters. Pomonic acid can be used in the research of atherosclerosis .
|
-
-
- HY-169499
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
(R)-2-(3-(2-Ethoxyphenoxy)piperidin-1-yl)pyrimidine-5-carboxylic Acid is an intermediate in the synthesis of the diacylglycerol acyltransferase 2 (DGAT-2) inhibitor Ervogastat.
|
-
-
- HY-107396
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
YM-750 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A .
|
-
-
- HY-N3806
-
|
|
Acyltransferase
ERK
|
Infection
Cardiovascular Disease
Cancer
|
|
Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 113 μM in an enzyme assay using rat liver microsomes . Enniatins B decreases the activation of ERK (p44/p42) .
|
-
-
- HY-161906
-
|
|
Acyltransferase
|
Cancer
|
|
SD-066-4 is an orally active acyltransferase inhibitor. SD-066-4 can be used in cancer research .
|
-
-
- HY-19286
-
|
F 12511
|
Acyltransferase
|
Cancer
|
|
Eflucimibe (F 12511) is a new acyl-coenzyme A cholesterol O-acyltransferase (ACAT) inhibitor. Eflucimibe can be used in the research of atherosclerosis .
|
-
-
- HY-N10224
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Terpendole C, produced by Albophoma yamanashiensis, shows potent inhibitory activity against acyl-CoA: cholesterol acyltransferase (ACAT) .
|
-
-
- HY-108339
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
PF-06471553 is a potent, selective and orally available monoacylglycerol acyltransferase 3 (MGAT3) inhibitor, with an IC50 of 92 nM.
|
-
-
- HY-125319
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Amidepsine A is a fungal metabolite isolated from the culture broth of Humicola sp. FO-2942 that inhibits Diacylglycerol acyltransferases (DGAT) activity .
|
-
-
- HY-15197
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
ABT-046 is a potent, selective, and orally active acyl CoA:diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC50s of both 8 nM against human and mouse DGAT-1 .
|
-
-
- HY-169813
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
Yakuchinone B is an Acyl-CoA: cholesterol O-acyltransferase (ACAT) inhibitor with hypocholesterolemic activity, which is found in the seeds of Zingiberaceae. Yakuchinone B inhibits rat hepatic ACAT with an IC50 value of 20.6 μM. Yakuchinone B is promising for research of hypercholesterolemia and atherosclerosis .
|
-
-
- HY-W014674
-
|
|
Acyltransferase
|
Cancer
|
|
2,6-Dichlorophenylacetic acid is an inhibitor of isopenicillin N synthase (IPNS) and acyl-CoA: 6-APA acyltransferase. 2,6-Dichlorophenylacetic acid is also part of a group of phenylacetate derivatives that have cytostatic activity against tumour cells .
|
-
-
- HY-N16614
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Ent-Calquiquelignan E (Compound 8) is a flavonoid lignan compound. Ent-Calquiquelignan E can selectively inhibit diacylglycerol acyltransferase 1 (DGAT1) with an IC50 of 71.5 μM. Ent-Calquiquelignan E can be used for the research of metabolic diseas .
|
-
-
- HY-112851
-
-
-
- HY-N6702
-
-
-
- HY-161175
-
|
|
Hedgehog
|
Cancer
|
|
IMP-1575 is the most potent Hedgehog acyltransferase (HHAT) inhibitor, with an IC50 of 0.75 μM for inhibition of purified HHAT. IMP-1575 can be used for the research of cancer .
|
-
-
- HY-129344
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
CL 277082 is a potent and selective acyl CoA:cholesterol acyltransferase (ACAT) inhibitor in microsomes. CL 277082 inhibits ACAT with IC50 values of 0.14 μM for intestinal mucosal microsomes, 0.74 μM for liver, and 1.18 μM for rat adrenal. CL 277082 is a ACAT-catalyzed cholesterol esterification and cholesterol absorption inhibitor .
|
-
-
- HY-23199
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
H2-003 is a diacylglycerol acyltransferase DGAT2 inhibitor with an IC50 value of 7.4 μM against human targets. H2-003 reduces triacylglycerol biosynthesis and inhibits lipid droplet formation. H2-003 can be used in studies related to hepatic steatosis and insulin resistance .
|
-
-
- HY-101627
-
-
-
- HY-16281
-
|
DuP 128
|
Acyltransferase
|
Metabolic Disease
|
|
Lecimibide (DuP 128) is a potent and specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor for antihyperlipidemia research .
|
-
-
- HY-U00430
-
-
-
- HY-145624
-
|
ION-769357
|
Acyltransferase
|
Metabolic Disease
|
|
Obeversen is an antisense oligonucleotide that inhibits the synthesis of diacylglycerol acyltransferase 2 (DGAT-2). Obeversen can be used in the research of nonalcoholic fatty liver disease .
|
-
-
- HY-12936
-
|
|
DNA/RNA Synthesis
Parasite
|
Infection
|
|
DDD100097 is a potent acyltransferase (TbNMT) inhibitor with an IC50 value of 2 nM. DDD100097 can significantly improve blood-brain barrier permeability. DDD100097 can be used in the study of African trypanosomiasis .
|
-
-
- HY-169085
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
LRAT-IN-1 (compound 1) is a retinol acyltransferase (LRAT) inhibitor (IC50=21.1 μM). LRAT-IN-1 provides anti-aging effects by inhibiting the esterification of retinol to form retinol esters, increasing the available retinol in the skin. Research on LRAT-IN-1 as an anti-aging ingredient in cosmetics .
|
-
-
- HY-162854
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Diacylglycerol acyltransferase inhibitor-2 (Example 8) is an inhibitor of Diacylglycerol Acyl Transferase 2 (DGAT2) with an IC50 value of 3.7 nM .
|
-
-
- HY-121762
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
NTE-122 (dihydrochloride) is an inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with the IC50 in liver and aorta of cholesterol-fed rabbits of 7.6nM, 4.4nM and 9.6 nM, respectively, that plays an important role in atherosclerosis .
|
-
-
- HY-121407
-
|
|
Acyltransferase
|
Infection
Cancer
|
|
Lateritin is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), isolated from the mycelial cake of Gibberella lateritium IFO 7188 . Lateritin also inhibits the growth of a mini-panel of human cancer cell lines, gram-positive bacteria, and Candida albicans .
|
-
-
- HY-N14614
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Pyripyropene B is a powerful acyl-CoA: cholesterol acyltransferase 2 (ACAT2) inhibitor found in the fungus Aspergillus fumigatus FO 1289. Pyripyropene B inhibits acyl-CoA: cholesterol acyltransferase with an IC50 of 117 nM .
|
-
-
- HY-N14648
-
-
-
- HY-N14649
-
-
- HY-N14573
-
-
- HY-N14793
-
-
- HY-N14794
-
-
- HY-N14581
-
-
- HY-N14580
-
-
- HY-N14525
-
|
|
Acyltransferase
|
Infection
|
|
Glisoprenin A is a cholesterol acyltransferase (ACAT) inhibitor, and it can inhibit the formation of Appressorium on the hydrophobic surface of Magnaporthegrisea .
|
-
- HY-N14578
-
-
- HY-N14584
-
-
- HY-N14813
-
|
|
Acyltransferase
|
Infection
|
|
Glisoprenin D is a cholesterol acyltransferase (ACAT) inhibitor, and it can inhibit the formation of Appressorium on the hydrophobic surface of Magnaporthegrisea .
|
-
- HY-N14574
-
|
|
Acyltransferase
|
Infection
|
|
Glisoprenin C is a cholesterol acyltransferase (ACAT) inhibitor, and it can inhibit the formation of Appressorium on the hydrophobic surface of Magnaporthegrisea .
|
-
- HY-N14816
-
|
|
Acyltransferase
|
Infection
|
|
Glisoprenin E is a cholesterol acyltransferase (ACAT) inhibitor, and it can inhibit the formation of Appressorium on the hydrophobic surface of Magnaporthegrisea .
|
-
- HY-119265
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC50 of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .
|
-
- HY-N9552
-
|
|
Acyltransferase
|
Infection
|
|
Purpactin A is a cholesterol acyltransferase (ACAT) inhibitor found in Pen. Purpurogenum FO-6 .
|
-
- HY-111417
-
-
- HY-19183
-
-
- HY-N10234
-
|
|
Acyltransferase
|
Infection
|
|
Phenylpyropene A, a fungal metabolite, is a potent acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor with an IC50 of 0.8 μM .
|
-
- HY-113671
-
|
|
Calcium Channel
Acyltransferase
|
Others
|
|
Belfosdil is an orally active and highly specific calcium channel blocker that also inhibits the activity of acyl coenzyme A cholesterol acyltransferase .
|
-
- HY-139024
-
-
- HY-139020
-
-
- HY-122078
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
FR-190809 is a potent, nonadrenotoxic, orally efficacious acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitor, with an IC50 of 45 nM .
|
-
- HY-N14968
-
|
|
Parasite
Fungal
|
Infection
|
|
Enniatin F has insecticidal and antifungal activity. Enniatin F also can inhibit acyl-CoA, cholesterol acyltransferase (ACAT) .
|
-
- HY-139025
-
-
- HY-139021A
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
ACAT-IN-4 hydrochloride (Example 208) is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor. ACAT-IN-4 hydrochloride inhibits NF-κB mediated transcription .
|
-
- HY-139021
-
-
- HY-139022
-
-
- HY-160804
-
|
|
Drug Intermediate
|
Cancer
|
|
Desmethyl nevanimibe (Compound 5) is the demethyl precursor of the sterol O-acyltransferase 1 (SOAT1) inhibitor Nevanimibe (PD-132301) .
|
-
- HY-118486
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
LDL-IN-1 (Compound 1) is an antioxidant, and is active against copper mediated LDL oxidation (IC50 = 52 μM). LDL-IN-1 is also an Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2) inhibitor, with IC50s of 60 μM. LDL-IN-1 can be used for anti-atherosclerotic research .
|
-
- HY-129295
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Amidepsine D is a fungal metabolite isolated from the culture broth of Humicola sp. FO-2942 that inhibits Diacylglycerol acyltransferases (DGAT) activity .
|
-
- HY-145624A
-
|
ION-769357 sodium
|
Acyltransferase
|
Metabolic Disease
|
|
Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease .
|
-
- HY-107572R
-
|
CI 976 (Standard)
|
Acyltransferase
Reference Standards
|
Metabolic Disease
|
|
PD 128042 (Standard) is the analytical standard of PD 128042. This product is intended for research and analytical applications. PD 128042 (CI 976) is a potent, orally active, and selective inhibitor of ACAT (acyl coenzyme A:cholesterol acyltransferase) with an IC50s of 73 nM. PD 128042 is also a potent LPAT (lysophospholipid acyltransferase) inhibitor. PD 128042 inhibits Golgi-associated LPAT activity (IC50=15 μM). PD 128042 inhibits multiple membrane trafficking steps, including ones found in the endocytic and secretory pathway .
|
-
- HY-106902
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
F-1394 is an orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor that inhibits dietary cholesterol absorption in mice. F-1394 can be used in cardiovascular disease research .
|
-
- HY-139019
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
ACAT-IN-2 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 187. ACAT-IN-2 inhibits NF-κB mediated transcription .
|
-
- HY-139026
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
ACAT-IN-9 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription .
|
-
- HY-139027
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription .
|
-
- HY-139027A
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
ACAT-IN-10 dihydrochloride is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 dihydrochloride weakly inhibits NF-κB mediated transcription .
|
-
- HY-139023
-
|
|
Acyltransferase
|
Inflammation/Immunology
|
|
ACAT-IN-6 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 200. ACAT-IN-6 potently inhibits NF-κB mediated transcription .
|
-
- HY-U00369
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
FCE 28654 is an inhibitor of acylCoA: cholesterol acyltransferase (ACAT), weakly inhibiting ACAT in microsomes from rabbit aorta and intestine, and monkey liver, with IC50s of 2.55, 1.08 and 5.69 μM, respcetively.
|
-
- HY-117466
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
FR186054 is an oral active acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor with the IC50 of 99 nM. FR186054 shows hypocholesterolemic effect and can be used for study of hypercholesterolemia and atherosclerosis .
|
-
- HY-120984
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
AcylCoA:cholesterol acyltransferase (ACAT) is an intracellular cholesteryl ester synthase tied closely to the absorption of dietary cholesterol.1 Oleic acid-2,6-diisopropylanilide is an inhibitor of acylCoA:cholesterol acyltransferase with an IC50 of 7 nM.2 When co-administered to rabbits or rats fed a high fat, high cholesterol diet, oleic acid-2,6-diisopropylanilide decreased low density lipoproteins and elevated high density lipoprotein levels when administered at 0.05%.
|
-
- HY-114619
-
|
Oleic acid anilide; OAA
|
Acyltransferase
|
Others
|
|
Oleyl anilide (Oleic acid anilide) is a toxic agent found in some stocks of toxic oil, which is associated with toxic oil syndrome (TOS). Oleyl anilide is an inhibitor of acyl-coenzyme A:cholesterol acyltransferase (ACAT) (IC50: 26 µM) .
|
-
- HY-N15411
-
|
|
Acyltransferase
Phytohormone
|
Metabolic Disease
|
|
Helminthosporol is a natural plant growth-regulator that can promote the growth of rice and lettuce seedlings. Helminthosporol can also inhibit the activity of acyl-CoA: cholesterol acyltransferase (ACAT) in rat liver microsomes and the synthesis of cholesterol esters in macrophages .
|
-
- HY-N14715
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Gypsetin can inhibit acylcoenzyme A, cholesterol acyltransferase (ACAT) activity, inhibit rat liver microbody ACAT with an IC50 of 18 μM, and its action is competitive with oleoyl-COA substrate, Ki value is 5.5 μM. Gypsetin also inhibits Oleic acid from forming cholesterol esters with an IC50 of 0.65 μM .
|
-
- HY-167664
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
KY-455 is a novel inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). KY-455 inhibita rabbit intestinal, hepatic, macrophage and adrenal ACAT with IC50 values of 0.4, 0.9, 2.9 and 4.1 μmol/L, respectively.
|
-
- HY-100400AR
-
|
|
Reference Standards
Acyltransferase
|
Cardiovascular Disease
|
|
K-604 (dihydrochloride) (Standard) is the analytical standard of K-604 (dihydrochloride). This product is intended for research and analytical applications. K-604 dihydrochloride is a potent and selective acyl-CoA:cholesterol acyltransferase 1 (ACAT-1) inhibitor with an IC50 of 0.45±0.06 μM.
|
-
- HY-19140
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
YM17E hydrochloride is an acyl CoA:cholesterol acyltransferase (ACAT) inhibitor, with IC50 of 44 nM. YM17E hydrochloride has hypocholesterolemic effect .
|
-
- HY-19112
-
|
|
Acyltransferase
|
Metabolic Disease
Endocrinology
|
|
447C88 is an acyl-coenzyme A cholesterol acyltransferase (ACAT) inhibitor with an IC50 of 23 nM. 447C88 can reduce plasma cholesterol levels and can be used in the research of endocrine and metabolic diseases such as hyperlipidemia .
|
-
- HY-108339R
-
|
|
Reference Standards
Acyltransferase
|
Metabolic Disease
|
|
PF-06471553 (Standard) is the analytical standard of PF-06471553 (HY-108339). This product is intended for research and analytical applications. PF-06471553 is a potent, selective and orally available monoacylglycerol acyltransferase 3 (MGAT3) inhibitor, with an IC50 of 92 nM.
|
-
- HY-181564
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
MGAT2-IN-7 (compound 27Q) is a substituted benzenesulfonamide compound and also a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) .
|
-
- HY-105445R
-
|
|
Reference Standards
Acyltransferase
|
Neurological Disease
|
|
CP-113818 (Standard) is the analytical standard of CP-113818 (HY-105445). This product is intended for research and analytical applications. CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease .
|
-
- HY-N6702S
-
|
|
Isotope-Labeled Compounds
Acyltransferase
|
Infection
|
|
Enniatin A- 13C36 is the 13C-labeled Enniatin A (HY-N6702). Enniatin A is a Fusarium mycotoxin. Enniatin A inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 22 μM in an enzyme assay using rat liver microsomes .
|
-
- HY-19251
-
|
|
Acyltransferase
|
Cardiovascular Disease
Metabolic Disease
|
|
CL-283796 is a potent and orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. CL-283796 reduces low-density lipoprotein (LDL) cholesterol without affecting cholesterol absorption in African green monkeys. CL-283796 can be used for hypercholesterolemia research .
|
-
- HY-123781A
-
|
|
Hedgehog
|
Cancer
|
|
RUSKI-201 dihydrochloride is a potent and specific Hedgehog acyltransferase (Hhat) inhibitor with an IC50 of 0.20 μM. RUSKI-201 dihydrochloride is able to block Hh signaling from Shh overexpressing cells and inhibits Hh palmitoylation. RUSKI-201 dihydrochloride is potential Hhat chemical probe in cells and can used in studies of Hhat catalytic function .
|
-
- HY-10038R
-
|
DGAT-1 Inhibitor 4a (Standard)
|
Acyltransferase
Reference Standards
|
Metabolic Disease
|
|
A 922500 (Standard) is the analytical standard of A 922500 (HY-10038). This product is intended for research and analytical applications. A 922500 (DGAT-1 Inhibitor 4a) is a potent, selective, and orally bioavailable diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC50s of 9 and 22 nM against human and mouse DGAT-1, respectively.
|
-
- HY-123781
-
|
|
Hedgehog
|
Cancer
|
|
RUSKI-201 is a potent and specific Hedgehog acyltransferase (Hhat) inhibitor, with an IC50 of 0.20 μM. RUSKI-201 is able to block Hh signaling from Shh overexpressing cells and inhibits Hh palmitoylation. RUSKI-201 is potential Hhat chemical probe in cells and can used in studies of Hhat catalytic function .
|
-
- HY-18366A
-
|
|
Hedgehog
|
Cancer
|
|
RU-SKI 43 hydrochloride is a potent and selective Hedgehog acyltransferase (Hhat) inhibitor with an IC50 of 850 nM. RU-SKI 43 hydrochloride reduces Gli-1 activation through Smoothened-independent non-canonical signaling and decreases Akt and mTOR pathway activity. RU-SKI 43 hydrochloride has anti-cancer activity .
|
-
- HY-18366
-
|
|
Hedgehog
|
Cancer
|
|
RU-SKI 43 is a potent and selective Hedgehog acyltransferase (Hhat) inhibitor with an IC50 of 850 nM. RU-SKI 43 reduces Gli-1 activation through Smoothened-independent non-canonical signaling and decreases Akt and mTOR pathway activity. RU-SKI 43 has anti-cancer activity .
|
-
- HY-100399AR
-
|
PD-132301 hydrochloride (Standard); ATR101 hydrochloride (Standard)
|
Reference Standards
Acyltransferase
Apoptosis
|
Cancer
|
|
Nevanimibe hydrochloride (Standard) is the analytical standard of Nevanimibe hydrochloride. This product is intended for research and analytical applications. Nevanimibe hydrochloride (PD-132301 hydrochloride) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe hydrochloride inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe hydrochloride induces cell apoptosis and has the potential for adrenocortical cancer .
|
-
- HY-149663
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
BMS-986172 is an orally active and selective Monoacylglycerol acyltransferase 2 (MGAT2) inhibitor with an IC50 of 4.6 nM and 20 nM for hMGAT2 and mMGAT2, respectively. BMS-986172 reduces food intake and body weight. BMS-986172 can be used for the researches of metabolic diseases, such as obesity .
|
-
- HY-13215
-
|
CI-1011; PD-148515
|
Acyltransferase
|
Cancer
|
|
Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively . Avasimibe can be used for the research of prostate cancer .
|
-
- HY-N6723S
-
|
|
Isotope-Labeled Compounds
|
Infection
|
|
Fumonisin B2- 13C34 is the 13C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .
|
-
- HY-109854A
-
|
(R)-Lisophylline
|
STAT
|
Metabolic Disease
Inflammation/Immunology
|
|
(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research .
|
-
- HY-110381
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
JNJ-DGAT2-A is a selective diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 value of 0.14 μM in human DGAT2-expressing Sf9 insect cell membranes. JNJ-DGAT2-A can be used for the research of triglyceride (TG) synthesis .
|
-
- HY-13912
-
IWP-2
Maximum Cited Publications
30 Publications Verification
|
Wnt
Porcupine
Casein Kinase
|
Cancer
|
|
IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ .
|
-
- HY-32219
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
T863 is an orally active, selective and potent DGAT1 (acyl-CoA:diacylglycerol acyltransferase 1) inhibitor with an IC50 of 15 nM. T863 has no inhibitory activity against human MGAT3, human DGAT2, or human MGAT2. T863 interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells .
|
-
- HY-129340
-
|
|
Acyltransferase
|
Cardiovascular Disease
|
|
AS-183 is an inhibitor of cholesterol acyltransferase (ACAT) (IC50=0.94 µM). AS-183 also inhibits the formation of cholesterol esters in HepG2, CaCo2 and THP-1 cells with IC50 values of 18.1, 25.5 and 34.5 µM, respectively. AS-183 can be used in the study of atherosclerosis and hypercholesterolemia .
|
-
- HY-113202
-
|
|
Endogenous Metabolite
PKC
GlyT
|
Neurological Disease
Metabolic Disease
|
|
Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
- HY-108341R
-
|
|
Reference Standards
Acyltransferase
|
Metabolic Disease
|
|
PF-06424439 (Standard) is the analytical standard of PF-06424439 (HY-108341). This product is intended for research and analytical applications. PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
|
-
- HY-103479
-
|
|
Acyltransferase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.
|
-
- HY-158790
-
|
|
Ferroptosis
|
Cancer
|
|
(R)-HTS-3 is an lysophosphatidylcholine acyltransferase 3 (LPCAT3) inhibitor, with an IC50 of 0.09 μM. (R)-HTS-3 suppresses the C20:4 content of PE, PC, and PS, while promoting a correspondingelevation in C22:4 phospholipids and a paradoxical increase in C20:4 phosphatidylinositol (PI) lipids .
|
-
- HY-108341AR
-
|
|
Reference Standards
Acyltransferase
|
Metabolic Disease
|
|
PF-06424439 methanesulfonate (Standard) is the analytical standard of PF-06424439 (methanesulfonate) (HY-108341A). This product is intended for research and analytical applications. PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM . PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate .
|
-
- HY-107396R
-
|
|
Reference Standards
Acyltransferase
|
Cardiovascular Disease
|
|
YM-750 (Standard) is the analytical standard of YM-750 (HY-107396). This product is intended for research and analytical applications. YM-750 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A .
|
-
- HY-107571
-
|
|
Acyltransferase
|
Cardiovascular Disease
Metabolic Disease
|
|
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .
|
-
- HY-N6719S
-
|
|
Isotope-Labeled Compounds
|
Infection
|
|
Fumonisin B1- 13C34 is the 13C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .
|
-
- HY-153855
-
|
RXC004
|
Wnt
Acyltransferase
Porcupine
|
Cancer
|
|
Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. Zamaporvint possesses multiple antitumor mechanisms and can be used in cancer research .
|
-
- HY-13912G
-
IWP-2
1 Publications Verification
|
Wnt
|
Cancer
|
|
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation .
|
-
- HY-13215R
-
|
CI-1011 (Standard); PD-148515 (Standard)
|
Acyltransferase
Reference Standards
|
Cancer
|
|
Avasimibe (Standard) is the analytical standard of Avasimibe. This product is intended for research and analytical applications. Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively . Avasimibe can be used for the research of prostate cancer .
|
-
- HY-113202S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
PKC
GlyT
|
Neurological Disease
Metabolic Disease
|
|
Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
- HY-N3807
-
|
|
Acyltransferase
ERK
NF-κB
|
Infection
Cardiovascular Disease
Cancer
|
|
Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes . Enniatin B1 crosss the blood-brain barrier . Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation .
|
-
- HY-N3806S
-
|
|
Isotope-Labeled Compounds
Acyltransferase
ERK
|
Infection
|
|
Enniatin B- 13C33 is the 13C-labeled Enniatin B (HY-N3806). Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 113 μM in an enzyme assay using rat liver microsomes . Enniatins B decreases the activation of ERK (p44/p42) .
|
-
- HY-101857R
-
|
MGAT2-IN-1 (Standard)
|
Reference Standards
Acyltransferase
|
Metabolic Disease
|
|
TP-020 (Standard) (MGAT2-IN-1 (Standard)) is the analytical standard of TP-020 (HY-101857). This product is intended for research and analytical applications. TP-020 (MGAT2-IN-1), a chemical probe, is an orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC50 of 7.8 and 2.4 nM for human and mouse MGAT2, respectively.
|
-
- HY-113202S1
-
|
|
Isotope-Labeled Compounds
GlyT
Endogenous Metabolite
PKC
|
Neurological Disease
Metabolic Disease
|
|
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .
|
-
- HY-162094
-
|
|
Acyltransferase
Bacterial
|
Infection
|
|
CMX410 is an orally active and selective Mycobacterium tuberculosis Pks13 acyltransferase domain inhibitor and anti-bacterial agent. CMX410 reacts with the catalytic serine of the Pks13-AT domain to form a stable β-lactam ring, disables the enzyme’s active site, reduces trehalose monomycolate and trehalose dimycolate levels, triggers cell lysis, and reduces intracellular bacterial burden. CMX410 can be used for the research of tuberculosis .
|
-
- HY-178712
-
|
|
Apoptosis
|
Cancer
|
|
CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β). CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC50 values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913). CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia .
|
-
- HY-112487
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Sandoz 58-035 is a selective acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor. Sandoz 58-035 inhibits this enzyme in intact cells and isolated microsomal fractions. Sandoz 58-035 blocks the esterification of exogenous vesicle-derived cholesterol and the incorporation of oleic acid into cellular cholesterol esters, reducing the formation and accumulation of cholesterol esters. Sandoz 58-035 causes a slight increase in cellular free cholesterol, and at high concentrations, it also causes a slight reduction in overall cellular protein synthesis. Sandoz 58-035 can be used in studies related to cellular cholesterol regulation .
|
-
- HY-107571R
-
|
|
Reference Standards
Acyltransferase
|
Cardiovascular Disease
Metabolic Disease
|
|
VULM 1457 (Standard) is the analytical standard of VULM 1457 (HY-107571). This product is intended for research and analytical applications. VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .
|
-
- HY-103479R
-
|
|
Reference Standards
Acyltransferase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
GOAT-IN-1 (Standard) is the analytical standard of GOAT-IN-1 (HY-103479). This product is intended for research and analytical applications. GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.
|
-
- HY-107176
-
|
(E)-HS-25
|
Drug Isomer
HCV
Acyltransferase
|
Infection
Metabolic Disease
|
|
(E)-Hyzetimibe ((E)-HS-25) (Compound I-1Z) is the trans isomer of Hyzetimibe (HY-107176A), a cholesterol-lowering agent. (E)-Hyzetimibe has cholesterol acyltransferase (ACTA) inhibitory activity, but its cholesterol-lowering effect is relatively weak. (E)-Hyzetimibe can inhibit the entry of hepatitis C virus (HCV) into host cells, and it has a synergistic effect when used in combination with interferon-α. (E)-Hyzetimibe can be used for the study of HCV infection .
|
-
- HY-175646
-
|
|
Acyltransferase
mTOR
Ribosomal S6 Kinase (RSK)
Apoptosis
|
Cancer
|
|
AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC50 of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys 228 and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib (HY-10201) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models .
|
-
- HY-N3807S
-
|
|
Isotope-Labeled Compounds
Acyltransferase
ERK
NF-κB
|
Infection
|
|
Enniatin B1- 13C34 is the 13C-labeled Enniatin B1 (HY-N3807). Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes . Enniatin B1 crosss the blood-brain barrier . Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation .
|
-
- HY-138942
-
|
|
Acyltransferase
|
Metabolic Disease
Inflammation/Immunology
|
|
PF-06427878 is an orally active, selective liver-targeted diacylglycerol acyltransferase 2 (DGAT2) inhibitor with IC50s of 99 nM and 202 nM for human and rat DGAT2, respectively. PF-06427878 shows greater than 470-fold selectivity for DGAT2 over DGAT1, MGAT1, MGAT2 and MGAT3. PF-06427878 can improve liver steatosis and function. PF-06427878 can be used for the study of nonalcoholic fatty liver diseases .
|
-
- HY-16278A
-
|
LCQ 908 sodium
|
Acyltransferase
BCRP
OAT
|
Infection
Metabolic Disease
|
|
Pradigastat sodium (LCQ 908 sodium) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
|
-
- HY-16278
-
|
LCQ-908
|
Acyltransferase
BCRP
OAT
|
Infection
Metabolic Disease
|
|
Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
|
-
- HY-118386
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
H2-005 is a compound that selectively inhibits diacylglycerol acyltransferase 2 (DGAT2) and has the activity to inhibit triacylglycerol synthesis in hepatocytes and preadipocytes. H2-005 significantly reduces triacylglycerol biosynthesis in HepG2 hepatocytes and 3T3-L1 preadipocytes. H2-005 exhibits specific inhibitory activity in DGAT2-overexpressing HEK293 cells. H2-005 almost completely inhibits lipid droplet formation in 3T3-L1 cells when co-treated with a DGAT1 inhibitor. H2-005 will contribute to DGAT2-related lipid metabolism research and the development of drugs to inhibit metabolic diseases .
|
-
- HY-N9530
-
-
- HY-112825
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
TSI-01 is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT)1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively). 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.
|
-
- HY-16278R
-
|
LCQ-908 (Standard)
|
Acyltransferase
BCRP
OAT
Reference Standards
|
Infection
Metabolic Disease
|
|
Pradigastat (Standard) is the analytical standard of Pradigastat. This product is intended for research and analytical applications. Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro .
|
-
- HY-D3391
-
|
|
Bacterial
|
Infection
|
|
RMR-Tre is a fluorescent probe targeting the mycobacterial acyltransferase Ag85. Under the catalysis of Ag85, RMR-Tre undergoes 6-position mycoloylation and anchors to the mycobacterial membrane, while achieving fluorescence activation by inhibiting the intramolecular twisted charge transfer state transition. RMR-Tre can distinguish live mycobacteria from dead ones through metabolism-driven labeling, enabling rapid, wash-free, low-background detection of viable bacteria. RMR-Tre reports the drug resistance of Mycobacterium tuberculosis via the trehalose catalytic shift activity readout associated with TreS. In addition, RMR-Tre can be combined with flow cytometry or high-content imaging techniques to visualize and quantitatively analyze the metabolic heterogeneity of Mycobacterium tuberculosis related to persistence and drug resistance. RMR-Tre is widely used in tuberculosis-related research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-13912G
-
IWP-2
1 Publications Verification
|
Fluorescent Dyes
|
|
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation .
|
-
- HY-D3391
-
|
|
Fluorescent Dyes
|
|
RMR-Tre is a fluorescent probe targeting the mycobacterial acyltransferase Ag85. Under the catalysis of Ag85, RMR-Tre undergoes 6-position mycoloylation and anchors to the mycobacterial membrane, while achieving fluorescence activation by inhibiting the intramolecular twisted charge transfer state transition. RMR-Tre can distinguish live mycobacteria from dead ones through metabolism-driven labeling, enabling rapid, wash-free, low-background detection of viable bacteria. RMR-Tre reports the drug resistance of Mycobacterium tuberculosis via the trehalose catalytic shift activity readout associated with TreS. In addition, RMR-Tre can be combined with flow cytometry or high-content imaging techniques to visualize and quantitatively analyze the metabolic heterogeneity of Mycobacterium tuberculosis related to persistence and drug resistance. RMR-Tre is widely used in tuberculosis-related research .
|
| Cat. No. |
Product Name |
Type |
-
- HY-13912G
-
IWP-2
1 Publications Verification
|
Biochemical Assay Reagents
|
|
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N6719
-
-
-
- HY-113054
-
-
-
- HY-N4193
-
-
-
- HY-113202
-
|
|
Microorganisms
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Endogenous Metabolite
PKC
GlyT
|
|
Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
-
- HY-117832
-
-
-
- HY-N3807
-
-
-
- HY-121254
-
-
-
- HY-N10788
-
-
-
- HY-N3806
-
-
-
- HY-N10224
-
-
-
- HY-125319
-
-
-
- HY-169813
-
-
-
- HY-N16614
-
-
-
- HY-N6702
-
-
-
- HY-N9530
-
-
-
- HY-N14614
-
-
-
- HY-N14648
-
-
-
- HY-N14649
-
-
-
- HY-N14573
-
-
-
- HY-N14793
-
-
-
- HY-N14794
-
-
-
- HY-N14581
-
-
-
- HY-N14580
-
-
-
- HY-N14525
-
-
-
- HY-N14578
-
-
-
- HY-N14584
-
-
-
- HY-N14813
-
-
-
- HY-N14574
-
-
-
- HY-N14816
-
-
-
- HY-N9552
-
-
-
- HY-N10234
-
-
-
- HY-N14968
-
-
-
- HY-N15411
-
-
-
- HY-N14715
-
|
|
Natural Products
Microorganisms
Source Classification
|
Acyltransferase
|
|
Gypsetin can inhibit acylcoenzyme A, cholesterol acyltransferase (ACAT) activity, inhibit rat liver microbody ACAT with an IC50 of 18 μM, and its action is competitive with oleoyl-COA substrate, Ki value is 5.5 μM. Gypsetin also inhibits Oleic acid from forming cholesterol esters with an IC50 of 0.65 μM .
|
-
-
- HY-129340
-
|
|
Natural Products
Microorganisms
Source Classification
|
Acyltransferase
|
|
AS-183 is an inhibitor of cholesterol acyltransferase (ACAT) (IC50=0.94 µM). AS-183 also inhibits the formation of cholesterol esters in HepG2, CaCo2 and THP-1 cells with IC50 values of 18.1, 25.5 and 34.5 µM, respectively. AS-183 can be used in the study of atherosclerosis and hypercholesterolemia .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-N6723S
-
|
|
|
Fumonisin B2- 13C34 is the 13C labeled Fumonisin B2 (HY-N6723) . Fumonisin B2, a mycotoxin produced by Fusarium moniliforme in various grains, is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis .
|
-
-
- HY-N6719S
-
|
|
|
Fumonisin B1- 13C34 is the 13C labeled Fumonisin B1 (HY-N6719) . Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin .
|
-
-
- HY-113202S
-
|
|
|
Stearoyl-L-carnitine-d3 is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .
|
-
-
- HY-113202S1
-
|
|
|
Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .
|
-
-
- HY-N6702S
-
|
|
|
Enniatin A- 13C36 is the 13C-labeled Enniatin A (HY-N6702). Enniatin A is a Fusarium mycotoxin. Enniatin A inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 22 μM in an enzyme assay using rat liver microsomes .
|
-
-
- HY-N3806S
-
|
|
|
Enniatin B- 13C33 is the 13C-labeled Enniatin B (HY-N3806). Enniatin B is a Fusarium mycotoxin. Enniatin B inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 113 μM in an enzyme assay using rat liver microsomes . Enniatins B decreases the activation of ERK (p44/p42) .
|
-
-
- HY-N3807S
-
|
|
|
Enniatin B1- 13C34 is the 13C-labeled Enniatin B1 (HY-N3807). Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes . Enniatin B1 crosss the blood-brain barrier . Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-145624
-
|
ION-769357
|
|
Antisense Oligonucleotides
|
|
Obeversen is an antisense oligonucleotide that inhibits the synthesis of diacylglycerol acyltransferase 2 (DGAT-2). Obeversen can be used in the research of nonalcoholic fatty liver disease .
|
-
- HY-145624A
-
|
ION-769357 sodium
|
|
Antisense Oligonucleotides
|
|
Obeversen sodium is an antisense oligonucleotide that inhibits the synthesis of Diacylglycerol acyltransferase 2 (DGAT-2). Obeversen sodium can be used in the research of nonalcoholic fatty liver disease .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13912G
-
IWP-2
1 Publications Verification
|
Wnt
|
Cancer
|
|
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: